This phase II trial is evaluating the effects of a new drug on anemia, in patients who have very low, low or intermediate risk Myelodysplastic Syndromes (MDS) .
This trial is treating patients with Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS).
This is a systemic therapy trial.
You may be excluded from this trial if:
- You have a certain disease or psychological condition.
- You have had certain treatments, surgical procedures or drugs.
- You have previously been treated (or are currently being treated) on a clinical trial.
Clinical trials have complex eligibility criteria - talk to your doctor about your interest in this trial.
Clinical Summary Read More
Use the hyperlinks, where available to access additional clinical trial information.
A Phase 2, Open-Label, Ascending Dose Study of KER-050 for the Treatment of Anemia in Patients With Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS)
Eligible participants will be assigned to receive either escalating or a confirmed dose of KER-050, subcutaneously, every 4 weeks for up to 4 cycles.